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Abstract 
The molecular basis of the regulation of cardiac L-type calcium channel activity by cAMP-dependent protein kinase (cA-PK) remains 
unclear. Direct cA-PK-dependent phosphorylation of the bovine ventricular a] subunit in vitro has been demonstrated in microsomal 
membranes, detergent extracts and partially purified (+)-[3H]PN 200-110 receptor preparations. Two 32P-labelled phosphopeptides, 
derived from cyanogen bromide cleavage, of 4.7 and 9.5 kDa were immunoprecipitated specifically by site-directed antibodies against he 
rabbit cardiac a~ subunit amino acid sequences 1602-1616 and 1681-1694, respectively, consistent with phosphorylation atthe cA-PK 
consensus ites at Ser j627 and Ser 17°°. No phosphopeptide products consistent with phosphorylation at three other C-terminal cA-PK 
consensus phosphorylation sites (Ser t575, Ser 1848 and Ser ]928) were identified using similar procedures suggesting that these sites are poor 
substrates for this kinase. Ser 1627 and Ser 17°° may represent sites of cA-PK phosphorylation i volved in the physiological regulation of 
cardiac L-type calcium channel function. 
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1. Introduction 
Autonomic nervous system control of the force of car- 
diac contraction and beat frequency is likely to occur 
through regulation of L-type voltage-sensitive calcium 
channel activity [1,2]. /3-Adrenergic stimulation results in 
increased L-type Ca 2÷ current due to modification of the 
millisecond kinetics of channel opening and closing and an 
increased availability of channels for opening [3]. These 
changes in kinetic properties are thought o be the result of 
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tein kinase; MOPS, 3-[N-morpholino]propanesulfonic acid; PBS, phos- 
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direct channel phosphorylation by cyclic AMP-dependent 
protein kinase (cA-PK) [1-3]. While there is evidence to 
implicate phosphorylation f both the a] [4,5] and /3 [6,7] 
subunits, the molecular basis of the regulation of cardiac 
L-type channel activity remains to be established. 
None of the phosphorylation sites for cA-PK identified 
in the skeletal muscle a I subunit [8-10] are present at 
equivalent positions in the cardiac a~ isoform [11]. How- 
ever, a number of consensus cA-PK sites present in the 
C-terminal sequence following the final putative trans- 
membrane segment (IVS6) [11] have been proposed to 
mediate cA-PK activation of this isoform [1]. In this study 
we have investigated the possibility that the cardiac a~ 
subunit is a substrate for cA-PK and have utilised antibody 
mapping methods in phosphopeptide analysis [9] to iden- 
tify two predominant cA-PK phosphorylation sites in the 
C-terminal region of this subunit. Parts of this work have 
been presented to the Biochemical Society [12]. 
2. Materials and methods 
[3 H]Azidopine (52 Ci/mmol) and [ y- 32 P]ATP, 3000 
Ci/mmol) were obtained from Amersham International. 
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( + )-Isopropyl-4-( 1,2,3,-benzoxadiazol-4-yl)- 1,4-dihydro- 
2,6-dimethyl-5-([ 3 H]methoxycarbonyl)pyridine-3-carboxylate 
((+)-[3H]PN 200-110, 85 Ci/mmol) was obtained from 
New England Nuclear. Unlabelled nitrendipine was kindly 
provided by Bayer. All chemicals were of the highest 
grade available. 
trifugation at 100000 × g for 30 min. Aliquots (100 /zl) 
wer  taken from the main solubilisation mixture and the 
non-specific binding incubation for assay of total radioac- 
tivity, protein-bound radioactivity and soluble protein. Pro- 
tein-bound radioactivity was assayed by the polyethylene 
glycol precipitation method of Curtis and Catterall [14]. 
2.1. Preparation of cardiac ~,entricular muscle microsomes 2.4. Purification of ( + )-[3H]PN 200-110 receptor 
Ventricular muscle microsomes were prepared from 
fresh bovine hearts by the method of Schneider and Hof- 
mann [ 13], using 40 mM 3-[ N-morpholino]propanesulfonic 
acid (MOPS) (pH 7.5) and 0.3 M sucrose instead of Tris 
and mannitol, respectively. All solutions contained the 
protease inhibitors: 10 mM EGTA, 1 mM benzamidine, 1 
mM iodoacetamide, 1 mM 1,10 phenanthroline, 0.1 mM 
phenylmethylsulfonyl fluoride and 10 /xg/ml soybean 
trypsin inhibitor. Microsomal membranes were used fresh 
or stored at a protein concentration of 20-40 mg/ml in 
0.3 M sucrose, 40 mM MOPS (pH 7.5) at -70°C. 
2.2. Measurement of (+)-[3H]PN 200-110 binding to 
membrane fractions 
Membranes were incubated at a protein concentration f
100 ~g/ml  with 0.2-2.0 nM (+)-[3H]PN 200-110 in the 
absence and presence of 1 /xM unlabelled nitrendipine in 
assay buffer (20 mM Tris-HC1 (pH 7.5), 1.5 mM CaCI 2) 
for 90 min at 4°C. Duplicate 400 /xl aliquots were vacuum 
filtered on Whatman GF/C  filters, washed twice with 5 ml 
20 mM Tris-HC1 (pH 7.5) and counted in Optiscint 'Safe' 
(Pharmacia) in a scintillation counter. 
2.3. Solubilisation and assay of ( + )-[3H]PN 200-110 
receptor 
Cardiac microsomal membranes (750 mg of protein) 
were diluted to a protein concentration of 2.5 mg/ml in a 
final concentration of 10 mM Hepes-Tris (pH 7.4), 185 
mM KCI, 1.5 mM CaC12. The following protease in- 
hibitors were included in all buffers: 1 /xg/ml antipain, 1 
mM benzamidine, 1 mM iodoacetamide, 1 /xg/ml leu- 
peptin, 1.5 /xM pepstatin A, 0.1 mM phenylmethylsulfonyl 
fluoride, 10 /xg/ml soybean trypsin inhibitor. All steps 
were carried out at 4°C. Membranes were incubated with 
0.25 nM (+)-[3H]PN 200-110 in the presence of 2 /~M 
diltiazem. An aliquot (1 ml) was taken and unlabelled 
nitrendipine added to give a final concentration of 1 ~M 
to determine non-specific binding. After incubation on ice 
for 45 min the two mixtures were subjected to ultracen- 
trifugation at 116 000 × g for 30 min. The pelleted mem- 
branes were resuspended in solubilisation buffer contain- 
ing 10 mM Hepes-Tris (pH 7.4), 185 mM KCI, 1.5 mM 
CaCI 2, 1% (w/v)  digitonin) at a detergent to protein ratio 
of 3:1 and incubated on ice for 45 min with occasional 
gentle agitation. Insoluble material was removed by cen- 
The main solubilisation mixture was diluted immedi- 
ately with 150 ml ice-cold dilution buffer (10 mM Hepes- 
Tris (pH 7.4), 1.5 mM CaC12) and applied onto a 150 ml 
column of DEAE-Sephadex 'Fast Flow' (Pharmacia) pre- 
equilibrated in 10 mM Hepes-Tris (pH 7.4), 1.5 mM 
CaCI 2, 92.5 mM KC1, 0.1% (w/v)digitonin at a flow-rate 
of 5 ml/min. The column was washed with 250 ml wash 
buffer (10 mM Hepes-Tris (pH 7.4), 1.5 mM CaCI 2, 0.1% 
(w/v) digitonin) at the same flow-rate. Elution of the 
column was performed at a flow-rate of 3 ml/min with 
250 mi wash buffer containing 0.15 M KCI. The eluate 
was loaded directly onto 3 ml wheat germ agglutinin 
(WGA)-Sepharose (Pharmacia). The column was washed 
with 40 ml wash buffer at a flow-rate of 2 ml/min, then 
eluted with 10 ml wash buffer containing 0.3 M N-acetyl- 
D-glucosamine ata flow-rate of 0.5 ml/min. Fractions (1.5 
ml) were collected and 50 /xl aliquots were counted for 
radioactivity. Where necessary, enriched (+)-[3H]PN 
200-110 receptor preparations were concentrated using 
Millipore Ultrafree C1 concentrators (> 10 kDa molecular 
mass exclusion) by centrifugation at 1500 × g at 4°C for 
60 min. 
2.5. Site-directed antibodies 
Four synthetic peptides corresponding to amino acid 
sequences 1602-1616 (IKTEGNLEQANEELR), 1681- 
1694 (LQAGLRTLHDIGPE) ,  1774-1789 
(SHEKLVDSTFTPSSYS) and 1889-1906 (LSYQD- 
DENRQLAPPEEEK) in the rabbit cardiac cq subunit [11] 
were prepared using the solid phase N~-fluoren - 
ylmethoxycarbonyl-polyamide ethod [15]. Each peptide 
was synthesised with a C-terminal cysteine residue to 
facilitate coupling to carrier protein and resin supports. 
Peptides were cleaved from the support using 60% (v/v)  
trifluoroacetic acid (TFA) in dichloromethane containing 
2% (w/v)  phenol and 2% (v/v)  ethanedithiol (EDT) after 
which amino acid side-chain protecting roups were re- 
moved in 95% TFA in H20 containing 2% phenol and 2% 
EDT. Peptides were washed in ether and characterised by 
high pressure liquid chromatography according to Davis et 
al. [16]. Peptides were conjugated to ovalbumin (molar 
ratio 8:1) with maleimidobenzoyl-N-hydroxysulfosuc- 
cinimide ester (Sulfo-MBS, Pierce) [17]. Antisera against 
ovalbumin conjugates were raised in New Zealand White 
rabbits by intravenous injection of 200 /xg conjugate in 10 
mM sodium phosphate (pH 7.2), 150 mM NaC1. Intra- 
R.N. Leach et al. / Biochimica et Biophysica Acta 1281 (1996) 205-212 207 
venous booster injections (200 /xg) were made after 1 
week and thereafter twice a week for 2 weeks. One week 
after the last injection rabbits, showing an immune re- 
sponse, were bled. Pre-immune serum was prepared from a 
bleed taken before immunisation. Serum was stored at 
-70°C. Antisera to the rabbit skeletal muscle oq amino 
acid sequence 1399-1418 (LDEFKAIWAEYD-  
PEAKGRIKC) was prepared using ovalbumin as carrier 
protein as described previously [18] as part of a separate 
study in collaboration with Dr. S.A. Baldwin and Professor 
D. Wray. 
Antibody titre was estimated in ELISA using microtitre 
plates coated with either peptide (2 /~g/ml) or DEAE 
Sephadex/WGA-Sepharose enriched calcium channel 
preparation (3 /zg protein/ml). Plates were blocked with 
0.5% casein, 10% calf serum, 0.05% Tween-20 in phos- 
phate-buffered saline (PBS; 40 mM sodium phosphate (pH 
7.4), 0.9% NaC1) for 1 h and then anti-peptide or control 
antisera were applied at the required dilution for 2 h. 
Antibody reaction was detected using sequential incuba- 
tions (1 h) of swine anti-rabbit IgG (1:1000 dilution, 
Dakopatts) and rabbit peroxidase anti-peroxidase conjugate 
(1:1000 dilution, Amersham) in 1% calf serum, 0.05% 
Tween-20, PBS at room temperature. Positive wells were 
identified by the development of blue coloration following 
the application of 10 mg/ml 3,3',5,5'-tetramethylbenzidine 
(Miles) in 0.1 M sodium acetate/citrate (pH 6.0), 0.0045% 
H202. Between steps wells were washed three times with 
0.05% Tween-20 in PBS. 
For immunoprecipitation experiments, immunoaffinity 
matrices were prepared according to Schneider et al. [19] 
by the covalent coupling of bound antibodies to protein 
A-Sepharose (6 ml serum/ml of gel) using dimethylpime- 
limidate (Pierce). Cardiac ventricular microsomes were 
incubated with 2.5 nM [3H]azidopine for 90 min at 4°C in 
the absence or presence of 1 /xM nitrendipine. Photo- 
affinity labelling of the channel protein was achieved by 
illumination of the mixture on ice with a 440W MBFR/U 
U.V. lamp at a distance of 12 cm for 3 rain. Labelled 
membranes were washed in incubation buffer (10 mM 
Hepes-Tris (pH 7.4), 185 mM KC1, 1.5 mM CaCI~) and 
solubilised as above. Photoaffinity labelled detergent ex- 
tracts (5000 dpm specifically labelled protein, 0.9 ml) were 
incubated with 0.1 ml immunoaffinity matrix for 16 h at 
4°C. After centrifugation at 11 000 × g for 1 min, super- 
natant was removed and the pellets washed twice in 1.5 ml 
radioimmune assay buffer (10 mM Hepes-Tris (pH 7.4), 
92.5 mM KC1, 0.5% digitonin (w/v)). Bound antigen was 
eluted with 2 × 0.5 ml 20 mM ethanolamine (pH 10), 
0.5% sodium deoxycholate. Aliquots (100 /zl) were 
counted for radioactivity in Optiscint 'Safe' (Pharmacia). 
Immunoblots were performed as described previously 
[20] using DEAE Sephadex/WGA-Sepharose enriched 
calcium channel preparation (0.5 /zg/lane) as antigen. 
Antibody overlay was with antiserum (1:100 dilution, 3 h) 
and anti-rabbit IgG (whole molecule) alkaline phosphatase 
conjugate (1:1000 dilution, 1 h) and immunoblots were 
developed using 5-bromo-4-chloro-3-indoyl phosphate/ 
nitroblue tetrazolium (Sigma Fast TM tablets). 
2.6. Phosphorylation of membrane-bound and enriched 
( + )-[3H]PN 200-110 receptor 
Phosphorylation protocols were based on that described 
by De Jongh et al. [21]. Cardiac ventricular microsomes 
(50-100 /xg of protein) or enriched ( + )-[ 3 H]PN 200-110 
receptor preparation (50-100 /xg of protein) were incu- 
bated in 0.1 /zM [y-32p]ATP (3000 Ci/mmol) in 50 mM 
Tris-HC1 (pH 7.5), protease inhibitors as described above, 
10 mM MgC12, 1 mM EGTA in a total volume of 150/zl. 
Reactions were initiated by the addition of cyclic AMP 
(125 pmol) or cA-PK catalytic subunit (0.5 p~g) and 
samples incubated at 25°C for 30 min. For immunoprecip- 
itation studies of intact (+)-[3H]PN 200-110 receptor the 
phosphorylation reaction was terminated by the addition of 
15 /xl 200 mM EDTA, 50 mM Tris-HCl (pH 7.5). To 
remove unreacted [T-32p]ATP prior to immunoprecipita- 
tion, 45 ~1 bovine serum albumin in reaction buffer was 
added to a final concentration of 1 mg/ml. The sample 
was applied to a 2 ml Sephadex G-25 column equilibrated 
with 25 mM Tris-HC1 (pH 7.5), 200 mM NaCI, 5 mM 
EDTA, 50 mM KF, 20 mM Na pyrophosphate, 0.5% 
(w/v)  digitonin and subjected to centrifugation at 1000 × g 
for 1 min. For immunoprecipitation studies of phospho- 
peptides derived from (+)-[3H]PN 200-110 receptor, the 
phosphorylation reaction was terminated by the addition of 
SDS-PAGE loading buffer and the 32 P-labelled oz I subunit 
separated by SDS-PAGE [22]. 
2.7. Immunoprecipitation of ~2p-labelled ( + )-[~H]PN 
200-110 receptor and peptides 
Aliquots (0.4 ml) of 32 P-labelled (+)-[3H]PN 200-110 
receptor (2000-5000 dpm) or peptides (500-1000 dpm) 
were immunoprecipitated by incubation with 50 ~1 im- 
munoaffinity matrix prepared as described above at 4°C 
for 16 h. The immunoaffinity matrix was washed with 25 
mM Tris-HCl (pH 7.5), 0.1% Triton X-100 and eluted with 
SDS-PAGE loading buffer for analysis by SDS-PAGE. 
2.8. Mapping of cA-PK phosphorylation sites within the 
primary sequence of the c~ 1 subunit 
Enriched ( + )-[ 3 H]PN 200-110 receptor was phospho- 
rylated as described above. 32p-labelled phosphoproteins 
were resolved by SDS-PAGE in 4-12% polyacrylamide 
gradients under reducing conditions [22] and transferred 
electrophoretically at 80 V for 2.5 h at 4°C to polyvinyl- 
idene difluoride membrane [23]. The phosphorylated a~ 
polypeptide was located on the filter by autoradiography. 
The filter immobilised, 32p labelled a~ subunit was ex- 
cised and incubated with 0.15 M cyanogen bromide (CNBr) 
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in 70% formic acid for 1 h at room temperature and 15 h 
at 4°C. CNBr cleavage products were eluted from the 
membrane in 250 mM Tris-HC1 (pH 9.5), 1% Triton 
X-100 and the pH re-adjusted to pH 7.5 immediately. 
Immunoaffinity matrices of anti-peptide and control anti- 
bodies, prepared as described above, were incubated with 
aliquots of 32 P-labelled CNBr peptides in the absence or 
presence of 1 /zg/ml corresponding competing peptide for 
16h at 4°C. Immunoprecipitation was assessed by the level 
of 32p label appearing in the matrix pellet after centrifuga- 
tion at 1000 × g for 1 min. 32 P-labelled phosphopeptides 
were eluted from the immunoaffinity matrices using SDS- 
PAGE loading buffer and subjected to SDS-PAGE on 15% 
polyacrylamide g ls. Gels were sliced (2 mm) and radioac- 
tivity in gel slices assessed by scintillation counting in 
Optiphase 'Safe'. Peptide masses were assigned by com- 
parison with molecular mass standards (Sigma Molecular 
Weight Markers for Peptides) (molecular mass range 2.5- 
17 kDa) and Dalton Mark VII-L (molecular mass range 
14.2-66 kDa). 
2.9. Protein determination 
Protein concentration was determined as described by 
Lowry et al. [24] or Bradford [25]. 
3. Results and discussion 
3.1. Characterisation ofanti-peptide antibodies 
Antisera were prepared against four synthetic peptides 
corresponding to sequences in the C-terminal region of the 
rabbit cardiac a~ subunit following the IVS6 putative 
transmembrane domain (1602-1616, 1681-1694, 1774- 
1789 and 1889-1906) (Fig. 1). Each sequence was se- 
lected to lie within a complete cyanogen bromide digestion 
product containing a consensus cA-PK phosphorylation 
site. All five anti-peptide antisera were shown to recognise 
the corresponding immunising peptide and enriched (+)-  
[3H]PN 200-110 receptor preparation in ELISA at dilu- 
tions of 1:1000 and 1:100 or less, respectively (not shown). 
In each case, the specificity of immune recognition was 
demonstrated by the inhibition of immune reaction when 
antibody was preincubated with its corresponding peptide 
and the lack of inhibition when antibodies were tested 
against non-target peptides. 
The specificity of all antibodies was further demon- 
strated in immunoprecipitation experiments. Immunoaffin- 
ity matrices of all five antibodies immunoprecipitated 
specifically calcium channel affinity labelled with 
[3H]azidopine and 32 P-labelled al subunit, phospho- 
rylated in the presence of cA-PK (Table 1). No specific 
immunoprecipitation was observed when an anti- 
Escherichia coli or protein A protein matrix was used 
(Table 1). Detection of a 200 kDa polypeptide in Western 
IVS6- - - t  Pill PI P I P I 
1575 1627 1700 1848 
J, 
I P I IC 
8242 4752 9515 15136 23385 Daltons 
Fig. 1. Location of site-directed antibody binding sites (inverted Y) and 
consensus cA-PK phosphorylation sites (P) in the C-terminal domain of 
the cardiac L-type Ca 2+ channel oq subunit. The bold line represents he 
polypeptide chain of the eq subunit. Tick marks indicate the position of 
methionine residues in the primary sequence of rabbit cardiac oq subunit 
[ 11] with distances between them being approximately proportional to the 
corresponding separations in the primary structure. Numbers below the 
line indicate the position of serines in consensus cA-PK phosphorylation 
sites in the rabbit primary sequence [ 11 ]. The predicted molecular mass of 
complete CNBr cleavage products containing cA-PK consensus sites are 
given at the foot of the figure. 
blots of enriched (+)-[3H]PN 200-110 receptor prepara- 
tion was demonstrated for two of the antibodies, anti-as 
1681-1694 and 1774-1789 in the absence but not the 
presence of the corresponding immunising peptide (Fig. 2). 
3.2. cA-PK-dependent phosphorylation of the ~1 subunit 
in cardiac microsomal membranes 
Phosphorylation of cardiac microsomal membranes in 




affinity labelled and phosphorylated calcium 
Antiserum Radioactivity immunoprecipitated (dpm) 
specific [3 H]azidopine 32 P-labelled 
labelled protein al subunit 
Anti-skeletal muscle 
oq 1399-1418 204 457 
Anti-a t 1602-1616 257 406 
Anti-a I 1681-1694 347 409 
Anti-a I 1774-1789 156 368 
Anti-a I 1889-1906 260 301 
Anti-E. coli 22 119 
Protein A-Sepharose 7 26 
Immunoprecipitations were carried out on antibody crosslinked cova- 
lently with dimethylpimelimidate to protein A-Sepharose. Cardiac micro- 
somal membrane proteins were labelled with [3H]azidopine in the ab- 
sence or presence of 1 ~M unlabelled nitrendipine to determine non- 
specific labelling. Affinity labelled proteins were immunoprecipitated 
from digitonin extracts. The nonspecific signal was subtracted from the 
total signal to yield the specific [3H]azidopine label immunoprecipitated. 
Data are means of two experiments. In phosphorylation experiments, 
cardiac microsomal proteins, phosphorylated in the presence of [~,- 
32 P]ATP and cA-PK catalytic subunit, were solubilised in digitonin as 
described in Section 2. 32 P-Labelled proteins (5000 dpm) were immuno- 
precipitated and proteins eluted from the immunomatrices were separated 
by SDS-PAGE on 4-12% linear acrylamide gradients. The region of gel 
corresponding to 200 + 10 kDa was excised and counted for radioactivity. 
Data are the means of two experiments. 
















Fig. 2. Immunoblot analysis of (+)-[3H]PN 200-110 receptor using 
anti-peptide antibodies. Enriched ( + )-[ 3 H]PN 200-110 receptor prepara- 
tion (2.5 /~g, 67 pmol/mg protein) was subjected to SDS-PAGE under 
reducing conditions on 4-12% linear acrylamide gradient gels followed 
by immunoblotting with antibodies to cardiac a u subunit peptides 1681- 
1694 (lanes 1 and 2) and 1774-1789 (lanes 3 and 4). Incubation with 
diluted antiserum (1:100) was performed in the presence (1, 3) or absence 
(2, 4) of 1 /xg/ml of the corresponding immunising peptide. Positions of 
molecular mass standards (kDa) are shown on the axis. F, ion front. 
and [y-32 P]ATP resulted in the labelling of multiple poly- 
peptides (Fig. 3A). A phosphorylated polypeptide of ap- 
proximately 200 kDa was immunoprecipitated by all five 
anti-c~] subunit antibodies (Table 1) and was identified as 
the major substrate for cA-PK on dilution of the phospho- 
rylated membrane protein sample before electrophoresis 
(Fig. 3B). No phosphorylation of the c~ 1 subunit was 
observed when cardiac ventricular microsomes were treated 
with cAMP only (Fig. 3B), indicating that endogenous 
cA-PK is not associated with the channel in the plasma 
membrane, cA-PK catalysed phosphorylation of the a1 
subunit was observed also in enriched (+)-[3H]PN 200- 
110 receptor preparation in the presence of exogenous 
cA-PK and [T-32p]ATP (Fig. 3C). In the absence of 
cA-PK catalytic subunit labelling of the ce~ subunit was 
not observed indicating that phosphorylation was not a 
result of endogenous kinase activity in the receptor prepa- 
ration. 
The cardiac a~ subunit has been reported to be a poor 
substrate for cA-PK [26-28]. It has been suggested [4,28] 
that this may be due to post-translational proteolytic pro- 
cessing of the C-terminal similar to that seen in skeletal 
muscle [21]. As a precaution i  the present study a cocktail 
of protease inhibitors was included in most buffers to 
reduce the effects of proteolysis. The presence of the 
C-terminal region, at least up to residues in the region 
1889-1906, was confirmed in this study by the recognition 
of the a~ subunit by the anti-c~ 1889-1906 antibody in 
ELISA (not shown) and in immunoprecipitation experi- 
ments (Table 1). These results suggest that cA-PK 
phosphorylation sites are accessible in membrane bound 
and detergent solubilised a] subunit in which the C-termi- 
nal region remains unproteolysed. 
3.3. Mapping of cA-PK phosphorylation sites 
Further mapping of cA-PK phosphorylation sites within 
the primary structure of the a t subunit by amino acid 
microsequencing and/or autoradiography of isolated 32 p_ 
labelled peptide fragments was precluded by the low yields 
of purified a~ polypeptide in purification experiments. As 
an alternative approach, we have sought to identify sites 
susceptible to cA-PK phosphorylation by immunoprecip- 
itation of 32 P-labelled phosphopeptides, derived from CNBr 
digestion of the a t subunit, using site-directed antibodies 
and peptide identification by scintillation counting of gel 
slices following peptide resolution by SDS-PAGE. 
Complete CNBr cleavage of the a~ subunit could not 
be achieved even with extended and repeated treatment of 
polyvinylidine difluoride membrane-bound protein with 
CNBr, nor in cleavage reactions of the soluble 32 P-labelled 
a~ subunit (Fig. 4A), suggesting that there was oxidative 
modification of some methionine residues during the work 
up before the cleavage reaction. As a consequence, the 
immunological analysis of 32p-labelled phosphopeptides 
was complicated by the possibility of immunoprecipitation 
of consensus phosphorylation sites in amino acid se- 
quences adjacent o the CNBr fragment argeted by the 
A B C 











!ii~ ~;~!i~i~  
i~;iii!i~i~i  ~i~i~i~i~iii~!~i 
 iiii!iii m 
!ii!! ~I i~i 
ili¸  i~i 
iiii~iiii!i!iii~iiii~i~!~ii!!ii~i(i~i(  
Fig. 3. Phosphorylation of membrane bound and enriched (+)-[3H]PN 
200-110 receptor preparations. ( + )-[ 3 H]PN 200-110 receptor prepara- 
tions were phosphorylated in the presence of 0.1 /zM [7-32p]ATP and 
analysed by SDS-PAGE under reducing conditions in 4-12% linear 
acrylamide gradients. Fixed and dried gels were exposed to Kodak 
X-Omat film with an intensifying screen. Positions of molecular mass 
standards (kDa) are shown on the axes. (A) Cardiac microsomal mem- 
branes (500 /xg protein/lane, 52 fmol (+)-[3H]PN 200-110 binding 
sites/mg protein) phosphorylated in the absence (lane 1) and presence 
(lane 2) of 0.5 /zg cA-PK catalytic subunit. (B) Cardiac microsomal 
membranes (5 /~g protein/lane, 65 fmol (+)-[3H]PN 200-110 binding 
sites/mg protein) phosphorylated as above in the absence (lanes 1 and 3) 
or presence of 125 pmol cyclic AMP (lane 2) or 0.5 /zg cA-PK catalytic 
subunit (lane 4). (C) Phosphorylation f enriched ( + )-[ 3 H]PN 200-110 
receptor preparation (20/xg protein/lane, 81 pmol ( + )-[3H]PN 200-110 
binding sites/mg protein) in the absence (lane 1) or presence (lane 2) of 
0.5 /xg cA-PK catalytic subunit. Direct comparison of the density of 
labelling of the a~ subunit between panels could not be made as there 
were differences in the radioactive specific activity of IT -32P]ATP used 
and in exposure times between experiments. 
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particular antibody employed. The criterion for the identi- 
fication of a phosphorylation site for cA-PK was that, for a 
given antibody, a 32 P-labelled phosphopeptide of the pre- 
dicted molecular mass for the consensus ite containing 
peptide from complete CNBr cleavage should be identified 
in the sample immunoprecipitated in the absence but not 
the presence of the corresponding immunising peptide. 
In four separate xperiments, phosphorylation at the 
consensus ite Ser  1627 (1619 IKK IWKRTSMKLLQ 1632 [1 1]) 
was indicated by immunoprecipitation of a 4.7 kDa CNBr 
32p-phosphopeptide with anti-a~ 1602-1616 antibody, in 
the absence but not the presence of competing peptide 
(Fig. 4B, predicted mass 4.752 kDa). In addition to Ser ~627, 
three threonine residues were also present in the target 
peptide but none was contained in a consensus equence 
and, therefore, were unlikely to be the substrate site of the 
cA-PK. A 32 P-labelled peptide of 9.5 kDa was immuno- 
precipitated specifically by anti-ce I 1681 - 1694 antibody in 
three separate xperiments (Fig. 4C, predicted mass 9.515 
kDa) suggesting possible cA-PK phosphorylation at the 
consensus site at Ser 17°° (169]IGPEIRRAISGDLTAI7°5 
[11]) also. Within this targeted peptide a further two serine 
and three threonine residues were present. None was pre- 
sent in a consensus equence and they were considered to 
be unlikely sites for cA-PK phosphorylation. 
Neither anti-skeletal muscle c~t 1399-1418 antibodies 
nor anti-cardiac c~j 1774-1789 or anti-c~j 1889-1906 
antibodies immunoprecipitated 32 P-labelled CNBr peptides 
of the predicted molecular mass (8.242, 15.136 and 23.385 
kDa, respectively, not shown). Since immunoprecipitation 
of intact 3:p-labelled c~ subunit was demonstrated for 
each antibody, we conclude that the absence of detectable 
phosphopeptides for consensus erines at positions 1575, 
1848 and 1928 indicates that these residues are likely to be 
poor substrates for cA-PK. This assumes equal efficiency 
of CNBr cleavage at each methionine residue and that the 
consensus erine residues are present in the bovine cardiac 
cq subunit. In all peptide immunoprecipitation experi- 
ments, no attempt was made to assign identities to 
immunoprecipitated products with molecular weights 
higher than the target peptide. There was no immuno- 
precipitation of 32 P-labelled peptides when a non-specific 
antiserum was used (Fig. 4D). 
The physiological significance of cA-PK catalysed 
phosphorylation at sites on the cardiac c~ 1 subunit identi- 
fied in this in vitro study remains to be established. 
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Fig. 4. Identification of 32 P-labelled CNBr cleavage products. CNBr digests of polyvinylidene difluoride membrane immobilised c~ t subunit were 
subjected to immunoprecipitation by anti-oq antibodies in the absence (closed symbols) or presence (open symbols) of 1 /xg/ml of the corresponding 
immunising peptide. Peptides eluted from the immunomatrices were separated by SDS-PAGE in 15% acrylamide gels, gels were sliced (2 mm) and slices 
counted for radioactivity. (A) Profile of 32 P-labelled CNBr cleavage products derived from the cardiac a I subunit. Peptides immunoprecipitated by 
anti-~ 1 1602-1616 (B), anti-oq 1681-1694 (C) and anti-E, coli (D) antibodies. Figure shows results representative of at least three experiments. Arrows 
indicate the position predicted for the complete CNBr digest product containing the consensus cA-PK phosphorylation site. F, ion front. 
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However, it has been demonstrated in stably transfected 
cell lines that the activity of the cloned cardiac L-type 
calcium channel a~ subunit when expressed alone is 
subject to cA-PK activity [4,5]. Furthermore, evidence that 
the C-terminal domain is involved in determining inactiva- 
tion properties of the cardiac calcium channel [29,30] is 
consistent with the possibility of regulation of channel 
function by phosphorylation in this domain. It is notewor- 
thy that the two consensus cA-PK phosphorylation sites 
Ser 1627 and Ser 17°° implicated in this study are conserved 
in the rabbit skeletal muscle and lung, human /J-cell and 
neuronal D, and rat aorta and brain BI and BII (Ser  1627 
only) oq subunit isoforms [11,31-37]. Although these 
residues are only minor sites for cA-PK phosphorylation in 
the skeletal muscle isoform [8-10] a participation in L-type 
channel regulation can not be ruled out. The possibility 
remains that there is isoform specific differential regula- 
tion of calcium channel activity by protein kinases [38,39]. 
By contrast, consensus ites at Ser 1575, Ser ~848 and Ser 1928, 
for which no evidence for cA-PK-dependent phosphoryla- 
tion was observed, are unique to the cardiac class a~ 
polypeptides [11,31-37]. It is likely that these residues 
play no part in mediating cA-PK regulation of channel 
activity. 
The identification of CNBr phosphopeptides by specific 
immunoprecipitation may provide an alternative approach 
to site-directed mutagenesis and expression of mutants to 
allow the physiological significance of particular channel 
phosphorylation events to be addressed. The immuno- 
logical approach may be particularly instructive should 
channel function be shown to be sensitive to phosphoryla- 
tion at multiple cA-PK sites, or should crosstalk between 
different signalling pathways be shown. 
In conclusion, we have shown that the o~ subunit of 
the cardiac L-type Ca 2 + channel is susceptible to phospho- 
rylation by cA-PK. Sites of cA-PK catalysed phosphoryla- 
tion have been localised to Ser 1627 and Ser 17°°. Other 
putative cA-PK sites in the o~ 1 subunit appear to be poor 
substrates. 
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